Fig. 3.

Inhibition of GRK-mediated phosphorylation of bROS by small molecules. A, inhibition of GRK1, GRK2, and GRK5 activity by balanol. Modulation of GRK2 (B), GRK5 (C), and GRK1 (D) activity by CMPD103A, CMPD101, or the negative control DMSO. In A and B, data are normalized to percent GRK2 and GRK5 activity based on a negative control containing no inhibitor and a positive control equivalent to background. The GRK1 data are normalized to the lowest concentration of balanol tested because of the increase in activity versus the control as also seen in D. Data shown are representative of three or more experiments performed in duplicate (Table 2). CMPD, compound.